Mexedrone

Pre-existing cardiovascular conditions — hypertension, arrhythmia, coronary artery disease, structural heart defects — are absolute contraindications. Tachycardia was the most consistently documented cardiovascular effect in the only clinical case series (7/11 patients). No controlled safety data exist to define a safe cardiovascular margin.

Personal or family history of psychotic disorders, schizophrenia spectrum conditions. Acute psychosis with supernatural/demonic themed hallucinations occurred in 3/11 analytically confirmed cases, none with prior psychiatric history. Risk likely elevated in those with existing vulnerability.

Stimulant compounds including cathinones carry a risk of precipitating manic episodes in individuals with bipolar disorder. No mexedrone-specific data exist; this is a cathinone class-level contraindication.

Hepatic impairment is expected to reduce mexedrone clearance due to CYP-dependent metabolism. No dosing adjustments have been studied. Patients with significant liver disease may experience amplified and prolonged effects.

Renal impairment may reduce excretion of unchanged mexedrone and its hydroxylated metabolites, potentially prolonging and intensifying effects. No dosing adjustments have been studied.

Individuals with CYP2C19 poor metabolizer phenotype are predicted to experience elevated mexedrone plasma concentrations at standard doses, increasing risk of adverse cardiovascular and neuropsychiatric effects. This prediction derives from in vitro metabolism data; no in vivo pharmacogenomic study has been conducted.

No reproductive toxicity, teratogenicity, or lactation transfer data exist for mexedrone. As with all synthetic cathinones, exposure during pregnancy or lactation is contraindicated in the absence of any safety data.

Concurrent use of monoamine oxidase inhibitors (MAOIs) with mexedrone is absolutely contraindicated. The combination of impaired monoamine degradation (MAOI) with enhanced serotonergic transmission (mexedrone SERT activity) creates potentially fatal serotonin syndrome and hypertensive crisis risk. No mexedrone-specific MAOI interaction data exist; this is a well-established class contraindication for all serotonergic stimulants.

Concurrent use of SSRIs or SNRIs with mexedrone produces additive serotonergic burden. Fluoxetine poses a dual risk as both an SSRI (pharmacodynamic) and CYP2C19 inhibitor (pharmacokinetic — reduced mexedrone clearance). Serotonin syndrome risk is dose-dependent.

The combination of tramadol and mexedrone produces additive serotonergic overload with risk of serotonin syndrome, hyperthermia, seizures, and potentially death. Tramadol inhibits serotonin reuptake (Baldo 2018) and lowers seizure threshold; mexedrone adds SERT inhibition and weak SERT releasing. No published mexedrone-tramadol fatality case report exists, but the mechanistic basis is well-established.